Health Condition 1: F01-F99- Mental, Behavioral and Neurodevelopmental disorders
Conditions
Interventions
Intervention1: Aripiprazole augmentation: Aripiprazole augmentation of ongoing anti -obsessive agents depending on dose. Group 1 with dose aripiprazole less than and equal to 5mg/day and in Group 2 do
Sponsors
GMC medical college
Eligibility
Inclusion criteria
Inclusion criteria: Patients of ocd diagnosed as per DSM 5, further treatment resistant OCD defined as patients who have undergone trial of first line therapies that is two different SSRI in adeqaute dose for adequate duration that is 10-12 weeks. patients who did not show adequate response on Ybocs score that is more than 35 % reduction on YBOCS score for full response and more than 25% to 35% reduction for partial response were enrolled ..Aripiprazole was added to ongoing treatment. Group 1 consisted to patients with ongoing treatment plus dose of aripiprazole less than equal to 5mg/day and group 2 consisted dose or aripiprazole more than 5mg to 10mg/day along with ongoing treatment. Response was noted at 2,4,8,12 weeks using YBOCS , CGI. BABS scale was used for assessment of insight and beliefs. GAF and WHOQOL-BREF was used for assessment of quality of life and wellbeing.
Exclusion criteria
Exclusion criteria: other psychiatric disorder, pregnant females, substance abuse,any other medical illness, other OCRD such as BDD,TTM,Hoarding disorder, and those who refused to give consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Severity and treatment response on YBOCS,CGI scaleTimepoint: Baseline,2,4,8,12 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| Assessment of insight on BABS scaleTimepoint: At baseline and 12 weeks;quality of lifeTimepoint: quality of life at baseline and 12 weeks on WHOQOL-BREF | — |
Countries
India
Contacts
Public ContactDr Ramandeep Kaur
Rajindra hospital
Outcome results
None listed